COVID-19 Drug API Market Outlook

The global COVID-19 Drug API market size was estimated at USD 6.9 billion in 2023 and is projected to reach USD 8.5 billion by 2032, driven by a compound annual growth rate (CAGR) of 2.3%. The growth factor for this market includes the ongoing need for effective treatments against COVID-19 and the continuous evolution of the virus, necessitating the development of new therapeutic agents and APIs. The urgency to manage the pandemic and prevent future outbreaks has significantly propelled the demand for COVID-19 drug APIs across the globe.

One of the primary growth factors for the COVID-19 Drug API market is the rapid advancement in biotechnology and pharmaceutical research. Companies and research institutions globally have been working tirelessly to develop effective antiviral agents, monoclonal antibodies, and other therapeutic drugs to combat COVID-19. The unprecedented speed at which vaccines and treatments have been developed and approved has created a robust pipeline of drug APIs specifically targeting COVID-19, thus driving market growth.

Another significant growth factor is the substantial financial investments made by governments and private entities in the healthcare sector. Governments worldwide have increased funding for COVID-19 research and development, resulting in accelerated drug discovery and development processes. Additionally, various pharmaceutical companies have received grants and subsidies to expedite the production of COVID-19 drug APIs. These financial incentives have been crucial in scaling up production capacities and ensuring the timely availability of therapeutic drugs.

Furthermore, the emergence of new COVID-19 variants has necessitated the continuous development and modification of existing treatments. With each new variant, the effectiveness of current drugs may diminish, prompting the need for updated APIs. This ongoing cycle of development and adaptation ensures a sustained demand for COVID-19 drug APIs. Additionally, the global push for booster vaccination drives and preventive treatments further boosts the market, as new formulations and combinations of APIs are required to enhance efficacy against emerging variants.

The integration of AI to Novel Coronavirus (COVID-19) and Epidemic management has emerged as a transformative approach in the pharmaceutical industry. AI technologies are being leveraged to accelerate drug discovery processes, optimize clinical trials, and predict potential outbreaks. By analyzing vast datasets, AI systems can identify promising drug candidates and streamline the development of APIs tailored to combat COVID-19. This technological advancement not only enhances the efficiency of research but also enables a more rapid response to the evolving nature of the virus, ensuring that effective treatments can be developed and distributed swiftly.

Regionally, North America remains a dominant player in the COVID-19 Drug API market, primarily due to its advanced healthcare infrastructure, significant R&D investments, and the presence of major pharmaceutical companies. Europe follows closely, with substantial contributions from countries like Germany, France, and the UK. However, the Asia Pacific region is expected to exhibit the fastest growth rate during the forecast period, driven by increasing healthcare investments, growing pharmaceutical manufacturing capabilities, and rising incidences of COVID-19 in densely populated countries like India and China.

Drug Class Analysis

The COVID-19 Drug API market, segmented by drug class, includes antivirals, antimalarials, corticosteroids, monoclonal antibodies, and other categories. Antivirals have been at the forefront of the market, given their critical role in inhibiting the replication of the SARS-CoV-2 virus. Remdesivir, for instance, became one of the first antiviral drugs approved for emergency use to treat COVID-19, significantly boosting the demand for antiviral APIs. Continuous research and new antiviral drug launches are expected to sustain the segmentÂ’s growth.

Antimalarials, notably hydroxychloroquine, initially garnered considerable attention as potential COVID-19 treatments, despite mixed clinical trial results. The early hype around these drugs led to a surge in production and demand for their APIs. However, as more data became available and alternative treatments were developed, the reliance on antimalarials has waned. Still

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since the first reported coronavirus case in Washington State on Jan. 21, 2020, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

The free database mapping COVID-19 treatment and vaccine development based on the global scientific research is available at https://covid19-help.org/.

Files provided here are curated partial data exports in the form of .csv files or full data export as .sql script generated with pg_dump from our PostgreSQL 12 database. You can also find .png file with our ER diagram of tables in .sql file in this repository.

Structure of CSV files

*On our site, compounds are named as substances

compounds.csv

1. Id - Unique identifier in our database (unsigned integer)

2. Name - Name of the Substance/Compound (string)

3. Marketed name - The marketed name of the Substance/Compound (string)

4. Synonyms - Known synonyms (string)

5. Description - Description (HTML code)

6. Dietary sources - Dietary sources where the Substance/Compound can be found (string)

7. Dietary sources URL - Dietary sources URL (string)

8. Formula - Compound formula (HTML code)

9. Structure image URL - Url to our website with the structure image (string)

10. Status - Status of approval (string)

11. Therapeutic approach - Approach in which Substance/Compound works (string)

12. Drug status - Availability of Substance/Compound (string)

13. Additional data - Additional data in stringified JSON format with data as prescribing information and note (string)

14. General information - General information about Substance/Compound (HTML code)

references.csv

1. Id - Unique identifier in our database (unsigned integer)

2. Impact factor - Impact factor of the scientific article (string)

3. Source title - Title of the scientific article (string)

4. Source URL - URL link of the scientific article (string)

5. Tested on species - What testing model was used for the study (string)

6. Published at - Date of publication of the scientific article (Date in ISO 8601 format)

clinical-trials.csv

1. Id - Unique identifier in our database (unsigned integer)

2. Title - Title of the clinical trial study (string)

3. Acronym title - Acronym of title of the clinical trial study (string)

4. Source id - Unique identifier in the source database

5. Source id optional - Optional identifier in other databases (string)

6. Interventions - Description of interventions (string)

7. Study type - Type of the conducted study (string)

8. Study results - Has results? (string)

9. Phase - Current phase of the clinical trial (string)

10. Url - URL to clinical trial study page on clinicaltrials.gov (string)

11. Status - Status in which study currently is (string)

12. Start date - Date at which study was started (Date in ISO 8601 format)

13. Completion date - Date at which study was completed (Date in ISO 8601 format)

14. Additional data - Additional data in the form of stringified JSON with data as locations of study, study design, enrollment, age, outcome measures (string)

compound-reference-relations.csv

1. Reference id - Id of a reference in our DB (unsigned integer)

2. Compound id - Id of a substance in our DB (unsigned integer)

3. Note - Id of a substance in our DB (unsigned integer)

4. Is supporting - Is evidence supporting or contradictory (Boolean, true if supporting)

compound-clinical-trial.csv

1. Clinical trial id - Id of a clinical trial in our DB (unsigned integer)

2. Compound id - Id of a Substance/Compound in our DB (unsigned integer)

tags.csv

1. Id - Unique identifier in our database (unsigned integer)

2. Name - Name of the tag (string)

tags-entities.csv

1. Tag id - Id of a tag in our DB (unsigned integer)

2. Reference id - Id of a reference in our DB (unsigned integer)
   

API Specification

Our project also has an Open API that gives you access to our data in a format suitable for processing, particularly in JSON format.

https://covid19-help.org/api-specification

Services are split into five endpoints:

• Substances - /api/substances

• References - /api/references

• Substance-reference relations - /api/substance-reference-relations

• Clinical trials - /api/clinical-trials

• Clinical trials-substances relations - /api/clinical-trials-substances

Method of providing data

• All dates are text strings formatted in compliance with ISO 8601 as YYYY-MM-DD

• If the syntax request is incorrect (missing or incorrectly formatted parameters) an HTTP 400 Bad Request response will be returned. The body of the response may include an explanation.

• Data updated_at (used for querying changed-from) refers only to a particular entity and not its logical relations. Example: If a new substance reference relation is added, but the substance detail has not changed, this is reflected in the substance reference relation endpoint where a new entity with id and current dates in created_at and updated_at fields will be added, but in substances or references endpoint nothing has changed.

The recommended way of sequential download

• During the first download, it is possible to obtain all data by entering an old enough date in the parameter value changed-from, for example: changed-from=2020-01-01 It is important to write down the date on which the receiving the data was initiated let’s say 2020-10-20

• For repeated data downloads, it is sufficient to receive only the records in which something has changed. It can therefore be requested with the parameter changed-from=2020-10-20 (example from the previous bullet). Again, it is important to write down the date when the updates were downloaded (eg. 2020-10-20). This date will be used in the next update (refresh) of the data.

Services for entities

List of endpoint URLs:

• /api/substances

• /api/references

• /api/substance-reference-relations

• /api/clinical-trials

• /api/clinical-trials-substances

Format of the request

All endpoints have these parameters in common:

• changed-from - a parameter to return only the entities that have been modified on a given date or later.

• continue-after-id - a parameter to return only the entities that have a larger ID than specified in the parameter.

• limit - a parameter to return only the number of records specified (up to 1000). The preset number is 100.

Request example:

/api/references?changed-from=2020-01-01&continue-after-id=1&limit=100

Format of the response

The response format is the same for all endpoints.

• number_of_remaining_ids - the number of remaining entities that meet the specified criteria but are not displayed on the page. An integer of virtually unlimited size.

• entities - an array of entity details in JSON format.

Response example:

{

"number_of_remaining_ids" : 100,

"entities" : [

{

"id": 3,

"url": "https://www.ncbi.nlm.nih.gov/pubmed/32147628",

"title": "Discovering drugs to treat coronavirus disease 2019 (COVID-19).",

"impact_factor": "Discovering drugs to treat coronavirus disease 2019 (COVID-19).",

"tested_on_species": "in silico",

"publication_date": "2020-22-02",

"created_at": "2020-30-03",

"updated_at": "2020-31-03",

"deleted_at": null

},

{

"id": 4,

"url": "https://www.ncbi.nlm.nih.gov/pubmed/32157862",

"title": "CT Manifestations of Novel Coronavirus Pneumonia: A Case Report",

"impact_factor": "CT Manifestations of Novel Coronavirus Pneumonia: A Case Report",

"tested_on_species": "Patient",

"publication_date": "2020-06-03",

"created_at": "2020-30-03",

"updated_at": "2020-30-03",

"deleted_at": null

},

]

}

Endpoint details

Substances

URL: /api/substances

Substances

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance publicly available dataset has 33 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors. This dataset requires a registration process and a data use agreement.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

Requesting Access to the COVID-19 Case Surveillance Restricted Access Detailed Data Please review the following documents to determine your interest in accessing the COVID-19 Case Surveillance Restricted Access Detailed Data file: 1) CDC COVID-19 Case Surveillance Restricted Access Detailed Data: Summary, Guidance, Limitations Information, and Restricted Access Data Use Agreement Information 2) Data Dictionary for the COVID-19 Case Surveillance Restricted Access Detailed Data The next step is to complete the Registration Information and Data Use Restrictions Agreement (RIDURA). Once complete, CDC will review your agreement. After access is granted, Ask SRRG (eocevent394@cdc.gov) will email you information about how to access the data through GitHub. If you have questions about obtaining access, email eocevent394@cdc.gov.

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affili

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F5505749%2F2b83271d61e47e2523e10dc9c28e545c%2F600x200.jpg?generation=1599042483103679&alt=media" alt="">

ALTADATA is a curated data marketplace where our subscribers and our data partners can easily exchange ready-to-analyze datasets and create insights with EPO, our visual data analytics platform.

COVID-19 Worldwide Daily Data

Daily global COVID-19 data for all countries, provided by Johns Hopkins University (JHU) Center for Systems Science and Engineering (CSSE). If you want to use the update version of the data, you can use our daily updated data with the help of api key by entering it via Altadata.

Overview

In this data product, you may find the latest and historical global daily data on the COVID-19 pandemic for all countries.

The COVID‑19 pandemic, also known as the coronavirus pandemic, is an ongoing global pandemic of coronavirus disease 2019 (COVID‑19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). The outbreak was first identified in December 2019 in Wuhan, China. The World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020 and a pandemic on 11 March. As of 12 August 2020, more than 20.2 million cases of COVID‑19 have been reported in more than 188 countries and territories, resulting in more than 741,000 deaths; more than 12.5 million people have recovered.

The Johns Hopkins Coronavirus Resource Center is a continuously updated source of COVID-19 data and expert guidance. They aggregate and analyze the best data available on COVID-19 - including cases, as well as testing, contact tracing and vaccine efforts - to help the public, policymakers and healthcare professionals worldwide respond to the pandemic.

Methodology

• Cases and Death counts include confirmed and probable (where reported)
• Recovered cases are estimates based on local media reports, and state and local reporting when available, and therefore may be substantially lower than the true number. US state-level recovered cases are from COVID Tracking Project.
• Active cases = total cases - total recovered - total deaths
• Incidence Rate = cases per 100,000 persons
• Case-Fatality Ratio (%) = Number recorded deaths / Number cases
• Country Population represents 2019 projections by UN Population Division, integrated to the JHU CSSE's COVID-19 data by ALTADATA

Data Source

• Johns Hopkins University Center for Systems Science and Engineering (JHU CSSE)
• United Nations Population Division

Related Data Products

• COVID-19 US Daily Data
• OECD, EU28, G20 Life Expectancy and Mortality Indicators

Suggested Blog Posts

• Bayesian Thinking During the Pandemic
• Impact of COVID-19 on California Electricity Demand
• Keep Calm and Look At The Fundamentals
• Markets In The Corona Virus Crisis

Data Dictionary

• Reported Date (reported_date) : Covid-19 Report Date
• Country_Region (country_region) : Country, region or sovereignty name
• Population (population) : Country populations as per United Nations Population Division
• Confirmed Case (confirmed) : Confirmed cases include presumptive positive cases and probable cases
• Active cases (active) : Active cases = total confirmed - total recovered - total deaths
• Deaths (deaths) : Death cases counts
• Recovered (recovered) : Recovered cases counts
• Mortality Rate (mortality_rate) : Number of recorded deaths * 100 / Number of confirmed cases
• Incident Rate (incident_rate) : Confirmed cases per 100,000 persons

Data from the COVID Tracking Project from The Atlantic. Made available through Socrata COVID-19 Plugin via API. Data dictionary available: https://covidtracking.com/about-data/data-definitions

From the Web site: The COVID Tracking Project is a volunteer organization launched from The Atlantic and dedicated to collecting and publishing the data required to understand the COVID-19 outbreak in the United States.

This data

The COVID Tracking Project collects information from 50 US states, the District of Columbia, and 5 other US territories to provide the most comprehensive testing data we can collect for the novel coronavirus, SARS-CoV-2. We attempt to include positive and negative results, pending tests, and total people tested for each state or district currently reporting that data.

Testing is a crucial part of any public health response, and sharing test data is essential to understanding this outbreak. The CDC is currently not publishing complete testing data, so we’re doing our best to collect it from each state and provide it to the public. The information is patchy and inconsistent, so we’re being transparent about what we find and how we handle it—the spreadsheet includes our live comments about changing data and how we’re working with incomplete information.

From here, you can also learn about our methodology, see who makes this, and find out what information states provide and how we handle it.

2019 Novel Coronavirus COVID-19 (2019-nCoV) Visual Dashboard and Map:
https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

• Confirmed Cases by Country/Region/Sovereignty
• Confirmed Cases by Province/State/Dependency
• Deaths
• Recovered

Downloadable data:
https://github.com/CSSEGISandData/COVID-19

Additional Information about the Visual Dashboard:
https://systems.jhu.edu/research/public-health/ncov

The current dataset contains Tweet IDs for tweets mentioning "COVID" (e.g., COVID-19, COVID19) and shared between March and July of 2020.Sampling Method: hourly requests sent to Twitter Search API using Social Feed Manager, an open source software that harvests social media data and related content from Twitter and other platforms.NOTE: 1) In accordance with Twitter API Terms, only Tweet IDs are provided as part of this dataset. 2) To recollect tweets based on the list of Tweet IDs contained in these datasets, you will need to use tweet 'rehydration' programs like Hydrator (https://github.com/DocNow/hydrator) or Python library Twarc (https://github.com/DocNow/twarc). 3) This dataset, like most datasets collected via the Twitter Search API, is a sample of the available tweets on this topic and is not meant to be comprehensive. Some COVID-related tweets might not be included in the dataset either because the tweets were collected using a standardized but intermittent (hourly) sampling protocol or because tweets used hashtags/keywords other than COVID (e.g., Coronavirus or #nCoV). 4) To broaden this sample, consider comparing/merging this dataset with other COVID-19 related public datasets such as: https://github.com/thepanacealab/covid19_twitter https://ieee-dataport.org/open-access/corona-virus-covid-19-tweets-dataset https://github.com/echen102/COVID-19-TweetIDs

Online platforms play a relevant role in the creation and diffusion of false or misleading news. Concerningly, the COVID-19 pandemic is shaping a communication network which reflects the emergence of collective attention towards a topic that rapidly gained universal interest. Here, we characterize the dynamics of this network on Twitter, analysing how unreliable content distributes among its users. We find that a minority of accounts is responsible for the majority of the misinformation circulating online, and identify two categories of users: a few active ones, playing the role of ‘creators’, and a majority playing the role of ‘consumers’. The relative proportion of these groups (approx. 14% creators—86% consumers) appears stable over time: consumers are mostly exposed to the opinions of a vocal minority of creators (which are the origin of 82% of fake content in our data), that could be mistakenly understood as representative of the majority of users. The corresponding pressure from a perceived majority is identified as a potential driver of the ongoing COVID-19 infodemic. Methods The datasets that we used in this work come from the COVID-19 Infodemics Observatory (https://covid19obs.fbk.eu/#/). Tweets associated with the COVID-19 pandemics (coronavirus, ncov, #Wuhan, covid19, COVID-19, SARSCoV2, COVID) have been automatically collected using the Twitter Filter API. It contains 7.7 million retweets in the case of USA, 300 thousand in the case of Italy and 900 thousand in the case of the UK. The time of the collection goes from the 22nd of January to the 22nd of May for the USA, while for Italy and the UK it goes from the 22nd of January to the 2nd of December. For each tweet we specified the ID code as well as the time at which it was created. In this dataset one can also find the tables necessary to reproduce exactly the figures in the paper.

Table of INEBase Deaths by Covid-19, autonomous community and city of death, gender and age. Comunidad y ciudad autónoma de defunción. Deaths according to Cause of Death

The report on North America COVID-19 Drug API covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

Context: COVID-19 Cases are on the rise in the U.S. This dataset allows one to model the spread of COVID-19 in America.

Content: The data shows the number of total confirmed covid-19 cases per day in the U.S.A.

Acknowledgement: This data comes from the Free COVID-19 API and can be found at https://documenter.getpostman.com/view/10808728/SzS8rjbc.

The global COVID-19 drug API market, encompassing key components like Hydroxychloroquine and Chloroquine Phosphate, experienced significant growth during the pandemic's initial phases. While the initial surge subsided as treatments evolved, the market retains a steady presence driven by ongoing research into antiviral therapies and the potential for future pandemics. The market's 5% CAGR suggests a consistent, albeit moderate, expansion. This growth is fueled by the continued need for readily available, affordable treatment options, particularly in developing nations. Tablet formulations currently dominate the market due to ease of administration and cost-effectiveness, though injectables represent a significant segment for specialized applications. Major players, including Shanghai Zhongxi Sunve Pharma Co., Ltd., Cinkate, and Fuan Pharmaceutical Group, are key contributors to the market's supply chain. Competition is expected to remain robust, with companies focusing on cost optimization, enhanced production capabilities, and potential expansion into novel antiviral APIs. Geographical distribution reveals a concentration in North America and Europe due to higher healthcare expenditure and established pharmaceutical infrastructure; however, the Asia-Pacific region presents a significant growth opportunity driven by increasing healthcare awareness and rising prevalence of infectious diseases. The market's future trajectory is intricately linked to global health policies, pandemic preparedness strategies, and the emergence of novel viral threats. Ongoing research into COVID-19 and other viral infections will shape future demand. While the initial pandemic-driven surge has stabilized, the market’s sustained growth reflects the inherent need for readily available antiviral APIs. Regulatory changes and the introduction of innovative drug delivery systems may also impact market segmentation and growth in the coming years. The focus remains on ensuring consistent supply chain resilience and affordability to ensure equitable access to essential antiviral medications globally.

Global COVID-19 Drug Associated APIs market size is expected to reach $9.08 billion by 2029 at 6.2%, elevated demand for active pharmaceutical ingredients (apis) driven by antivirals, antimalarials, and respiratory medications in the covid-19 drug market

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. More information available at https://coronavirus.dc.gov.Data for overall Coronavirus cases and testing results. Demographics are presented by race, gender, ethnicity and age. Additional variables for personnel in the public safety, medical and human service workforce. District agencies are Metropolitan Police Department (MPD), Fire and Emergency Medical Services (FEMS), Department of Corrections (DOC), Department of Youth Rehabilitation Services (DYRS) and Department of Human Services (DHS). Data for Saint Elizabeth's Hospital available. DYRS, DOC and DHS further report on its resident populations. Visit https://coronavirus.dc.gov/page/coronavirus-data for interpretation analysis.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

Key figures on laboratory-confirmed cases, hospitalisations, deaths, tests, vaccinations, relevant virus variants, Re values, contact tracing (isolation and quarantine), hospital capacity and the international situation.

Documentation

• data documentation
• release notes
• data context API

SummaryTotal ever COVID-19 cases and deaths at Maryland congregate living facilities.DescriptionDeprecated as of November 17, 2021.The Outbreak-Associated Cases in Congregate Living data dashboard on coronavirus.maryland.gov was redesigned on 11/17/21 to align with other outbreak reporting. Visit MD COVID-19 Congregate Outbreaks to view Outbreak-Associated Cases in Congregate Living data as reported after 11/17/21.The MD COVID-19 Congregate Cases and Deaths total Summary data layer is the cumulative total of COVID-19 cases and deaths that have occured in nursing homes, assisted living facilities, group homes of 10 or more and state and local facilities. Data are reported to MDH by local health departments, the Department of Public Safety and Correctional Services and the Department of Juvenile Services and are updated once weekly.COVID-19 is a disease caused by a respiratory virus first identified in Wuhan, Hubei Province, China in December 2019. COVID-19 is a new virus that hasn't caused illness in humans before. Worldwide, COVID-19 has resulted in thousands of infections, causing illness and in some cases death. Cases have spread to countries throughout the world, with more cases reported daily. The Maryland Department of Health reports daily on COVID-19 cases by county.

Get key insights from Market Research Intellect's COVID-19 Drug API Market Report, valued at USD 4.5 billion in 2024, and forecast to grow to USD 7.2 billion by 2033, with a CAGR of 6.5% (2026-2033).

The Paxlovid API market is experiencing significant growth, driven by the ongoing demand for effective treatments against COVID-19. While precise market size figures for 2025 are unavailable, based on industry analysis of similar pharmaceutical APIs and considering a plausible CAGR (let's assume a conservative 15% CAGR, reflecting a potential slowdown from peak pandemic demand), we can estimate a 2025 market size of approximately $500 million. This value reflects both the continued need for treatment in high-risk populations and the potential for broader use as a prophylactic treatment. The market is expected to continue expanding throughout the forecast period (2025-2033), although at a potentially decelerating rate, as COVID-19 transitions towards a more endemic stage. Key players like Pfizer, Nanjing Hicin Pharmaceutical, Lepu Medical, HAS Biotech, and Novasep are actively shaping the market landscape, influencing pricing strategies and production capacities. Factors such as evolving treatment guidelines, the emergence of new variants, and the development of competing antiviral therapies will significantly impact market growth in the coming years. The growth trajectory will be influenced by several factors. Government policies concerning healthcare spending and access to antiviral medications, alongside the evolving epidemiological situation, play crucial roles. Furthermore, technological advancements in API synthesis and manufacturing processes could lead to cost reductions and increased production efficiency, impacting market competitiveness and overall pricing. The geographic distribution of the market is likely skewed towards regions with higher initial infection rates and greater healthcare infrastructure. However, increased global demand is expected to lead to wider geographic distribution across various regions over the forecast period. Continued research into the long-term effects of COVID-19 and the potential for repurposing Paxlovid API for other viral infections could also open up new market avenues.